ClinicalTrials.gg

Program

dulpatatug

Also written as “HLX22” and “HLX87 + HLX22”.

In Fosun Pharma's pipeline, dulpatatug. Its studies are mostly in Breast Neoplasms · Stomach Neoplasms, led by Fosun Pharma.

Furthest: phase 3, since Jul 25, 20246 company-led studies, 5 open or runningNext primary completion: Jun 1, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Fosun Pharma65 open or runningphase 3since Jul 25, 2024Apr 4, 2019Jun 1, 2027phase 3 · NCT06532006
  • Named in Fosun Pharma’s own pipeline as HLX22 (dulpatatug), phase 3, as of Sep 21, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Apr 4, 2019First study: phase 1 study in Solid TumorFirst studyNCT03916094 · 11 enrolled · China
  2. May 21, 2021Phase 2 study in Stomach NeoplasmsNCT04908813 · 150 enrolled · China
  3. Jul 25, 2024Phase 3 study in Stomach NeoplasmsNCT06532006 · 550 planned · United States, Argentina, Australia and more
  4. Feb 12, 2025Phase 2 study in HER2-low Hormone Receptor Positive Breast CancerNCT06832202 · 50 planned · China
  5. Dec 8, 2025Phase 3 study in Breast NeoplasmsNCT07294508 · 706 planned · China
  6. Sep 13, 2026Phase 2 study in Breast NeoplasmsNCT07824869 · 90 planned

Ahead

  1. Jun 1, 2027Primary completion: phase 2 study in HER2-low Hormone Receptor Positive Breast CancerNCT06832202
  2. Jun 1, 2027Primary completion: phase 3 study in Stomach NeoplasmsNCT06532006
  3. Jan 15, 2028Primary completion: phase 3 study in Breast NeoplasmsNCT07294508
  4. Mar 31, 2028Primary completion: phase 2 study in Breast NeoplasmsNCT07824869

TargetBeta

“dulpatatug”the company's pipeline, read by Claude · source
“A humanized immunoglobulin (lg) G1 monoclonal antibody directed against the human epidermal growth factor receptor 2 (HER2), with potential immunomodulating and antineoplastic activity. Upon administration, dulpatatug targets and binds to HER2 on tumor cell surface. This may induce a cytotoxic T-…”NCIt, read by Claude
“A humanized immunoglobulin (lg) G1 monoclonal antibody directed against the human epidermal growth factor receptor 2 (HER2), ”NCIt, by rule

Other programs on ERBB2

ProgramCompanyFurthest phaseStudies
TrastuzumabruleHoffmann-La Rochephase 485
pertuzumabruleHoffmann-La Rochephase 456
trastuzumab deruxtecanruleDaiichi Sankyophase 449
tucatinibrulePfizerphase 425
disitamab vedotinRemeGenphase 336
trastuzumab rezetecanruleJiangsu HengRui Medicinephase 336
Lutetium-177Novartisphase 324
trastuzumab brengitecanSichuan Biokin Pharmaceuticalphase 321
Gallium-68Philogenphase 317
zongertinibruleBoehringer Ingelheimphase 315
Anti-HER2/Topoisomerase I Inhibitor ADC TQB2102Sino Biopharmaceuticalphase 313
sunvozertinibruleDizal Pharmaceuticalsphase 312

Studies

All 6 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07824869Breast Neoplasms2Not yet recruitingMar 31, 202890
NCT07294508Breast Neoplasms · China3RecruitingJan 15, 2028706
NCT06832202HER2-low Hormone Receptor Positive Breast Cancer · China2RecruitingJun 1, 202750
NCT06532006Stomach Neoplasms · United States, Argentina, Australia and more3RecruitingJun 1, 2027550
NCT04908813Stomach Neoplasms · China2Active, not recruitingDec 2024150
NCT03916094Solid Tumor · China1CompletedJan 4, 202111

How it is read

Names in the registry

  • “HLX22”, 5 entries
  • “HLX87 + HLX22”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.